Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042861 · ClinicalTrials.gov registry record · Phase 1
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00042861: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00042861 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042861, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining UCN-01, fluorouracil, and leucovorin in treating patients who have metastatic or unresectable solid tumors.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG 7-hydroxystaurosporine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-08 |
| Phase | Phase 1 |
What the finished NCT00042861 record still lists
NCT00042861 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00042861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00042861 about?
NCT00042861 is a clinical study titled "UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors". RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase I t...
What is the current status of trial NCT00042861?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-08.
What interventions are being tested in trial NCT00042861?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), 7-hydroxystaurosporine (DRUG).
Who is sponsoring clinical trial NCT00042861?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia